Case Report

Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report

*Author for correspondence:s.

E-mail Address: carleny@hs.uci.edu

https://orcid.org/0000-0003-1950-8819

Department of Neuro-Oncology, University of California, Irvine, CA 92868-3201, USA

Search for more papers by this author

Silin Bao

Department of Internal Medicine. Community Regional Medical Center, Fresno, CA 93721, USA

Search for more papers by this author

Mya Sandi Aung

California Health Sciences University, College of Osteopathic Medicine, Clovis, CA 93611, USA

Search for more papers by this author

Rhea Shishodia

California Health Sciences University, College of Osteopathic Medicine, Clovis, CA 93611, USA

Search for more papers by this author

Xiao-Tang Kong

Department of Neuro-Oncology, University of California, Irvine, CA 92868-3201, USA

Search for more papers by this author

Published Online:26 Jan 2024https://doi.org/10.2217/pme-2023-0137

View article

Abstract

Erdheim-Chester disease (ECD) is an exceedingly rare non–Langerhans cell CD68⁺ CD1a^- S100^- histiocytic multi-organ disease. Diagnosis of ECD is often delayed due to non-specific radiographic findings and heterogeneous lesional tissue. Increasingly, the role of genomic alterations is being recognized for both diagnosis and treatment of ECD. More than half of ECD patients harbor the BRAF^V600E mutation. Evaluation for this mutation be can falsely negative on immunohistochemical staining and confirmation with molecular analyses is recommended. We present a case of the 44 year-old male with BRAF^V600E-positive ECD treated successfully with steroids followed by single-agent dabrafenib.

Plain language summary

Erdheim-Chester disease (ECD) is an exceedingly rare type of histiocytosis (a disorder of white blood cells). The diagnosis of ECD can be challenging because tissue biopsy may not provide a definitive diagnosis. Currently, genetic mutations can be used to support both diagnosis and treatment. We present a case of the 44 year-old male with BRAF V600E -positive ECD who was treated successfully with steroids followed by dabrafenib.

Keywords:

References

1. Estrada-Veras JI, O'brien KJ, Boyd LC et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1(6), 357–366 (2017).
Medline CASGoogle Scholar
2. Munoz J, Janku F, Cohen PR, Kurzrock R. Erdheim-Chester disease: characteristics and management. Mayo Clin. Proc. 89(7), 985–996 (2014).
Medline CASGoogle Scholar
3. Al Bayati A, Plate T, Al Bayati M, Yan Y, Lavi ES, Rosenblatt JD. Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement. Mayo Clin Proc Innov Qual Outcomes 2(3), 303–308 (2018).
MedlineGoogle Scholar
4. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood 135(16), 1311–1318 (2020).
MedlineGoogle Scholar
5. Goyal G, Heaney ML, Collin M et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135(22), 1929–1945 (2020).
Medline CASGoogle Scholar
6. Cohen Aubart F, Idbaih A, Emile JF et al. Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro Oncol 23(9), 1433–1446 (2021).
MedlineGoogle Scholar
7. Goyal G, Young JR, Koster MJ et al. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin. Proc. 94(10), 2054–2071 (2019).
MedlineGoogle Scholar
8. Aktan Suzgun M, Everest E, Kucukyurt S et al. Erdheim-Chester disease of brain parenchyma without any systemic involvement: a case report and review of literature. Neuropathology doi:10.1111/neup.12930 (2023).
Google Scholar
9. Gray JCR, Kim J, Digianvittorio M et al. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging. J Natl Compr Canc Netw 18(6), 650–655 (2020).
MedlineGoogle Scholar
10. Cangi MG, Biavasco R, Cavalli G et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann. Rheum. Dis. 74(8), 1596–1602 (2015).
Medline CASGoogle Scholar
11. Oneal PA, Kwitkowski V, Luo L et al. FDA Approval Summary: vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. Oncologist 23(12), 1520–1524 (2018).
Medline CASGoogle Scholar
12. Bhatia A, Hatzoglou V, Ulaner G et al. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol 22(7), 979–992 (2020).
Medline CASGoogle Scholar
13. Cohen-Aubart F, Emile JF, Carrat F et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am. J. Hematol. 93(5), E114–E117 (2018).
MedlineGoogle Scholar
14. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120(13), 2700–2703 (2012).
Medline CASGoogle Scholar
15. Boyd LC, O'brien KJ, Ozkaya N et al. Neurological manifestations of Erdheim-Chester Disease. Ann Clin Transl Neurol 7(4), 497–506 (2020).
MedlineGoogle Scholar
16. Tavakoli M, Roghaee S, Gunturu M, Omuro AM, Lam BL, Mendoza-Santiesteban CE. Erdheim-Chester Disease Presenting With Diplopia: A Challenging Diagnosis With Effective Treatment. J. Neuroophthalmol. 41(3), e324–e325 (2021).
MedlineGoogle Scholar
17. Salama H, Fahed Alzayed M, Alharbi KG et al. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib. Am J Case Rep 23, e935090 (2022).
MedlineGoogle Scholar
18. Berti A, Cavalli G, Guglielmi B et al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology 6(6), e1318237 (2017).
MedlineGoogle Scholar
19. Miller RC, Villa S, Kamer S et al. Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study. Radiother. Oncol. 80(3), 323–326 (2006).
MedlineGoogle Scholar
20. Mascalchi M, Nencini P, Nistri M, Sarti C, Santoni R. Failure of radiation therapy for brain involvement in Erdheim Chester disease. J. Neurooncol. 59(2), 169–172 (2002).
MedlineGoogle Scholar
21. Badzek S, Misir-Krpan A, Krajina Z, Radman I, Stern-Padovan R, Dotlic S. Erdheim-Chester disease and concomitant tuberculosis successfully treated with chemotherapy and long-term steroids. Coll Antropol 31(2), 621–623 (2007).
MedlineGoogle Scholar
22. Cuoco JA, Klein BJ, Busch CM, Guilliams EL, Olasunkanmi AL, Entwistle JJ. Corticosteroid-Induced Regression of Glioblastoma: A Radiographic Conundrum. Front Oncol 9, 1288 (2019).
MedlineGoogle Scholar
23. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 4(2), 233–242 (2011).
Medline CASGoogle Scholar
24. Arnaud L, Hervier B, Neel A et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 117(10), 2778–2782 (2011).
Medline CASGoogle Scholar
25. Haroche J, Cohen-Aubart F, Emile JF et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121(9), 1495–1500 (2013).
Medline CASGoogle Scholar
26. Cohen-Aubart F, Emile JF, Maksud P et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology 83(14), 1294–1296 (2014).
MedlineGoogle Scholar
27. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124(4), 483–492 (2014).
Medline CASGoogle Scholar
28. Cao XX, Niu N, Sun J et al. Clinical and positron emission tomography responses to long-term high-dose interferon-alpha treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis 14(1), 11 (2019).
MedlineGoogle Scholar
29. Cohen Aubart F, Idbaih A, Galanaud D et al. Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology 95(20), e2746–e2754 (2020).
MedlineGoogle Scholar
30. Pegoraro F, Papo M, Maniscalco V, Charlotte F, Haroche J, Vaglio A. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia 34(11), 2840–2857 (2020).
Medline CASGoogle Scholar
31. Diamond EL, Subbiah V, Lockhart AC et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol 4(3), 384–388 (2018).
MedlineGoogle Scholar
32. Tzoulis C, Schwarzlmuller T, Gjerde IO et al. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes 8, 171 (2015).
MedlineGoogle Scholar
33. Dion E, Graef C, Miquel A et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 238(2), 632–639 (2006).
MedlineGoogle Scholar
34. Parks NE, Goyal G, Go RS, Mandrekar J, Tobin WO. Neuroradiologic manifestations of Erdheim-Chester disease. Neurol Clin Pract 8(1), 15–20 (2018).
MedlineGoogle Scholar
35. The Lancet H. Orphan drug approval for Erdheim-Chester disease. Lancet Haematol 4(12), e562 (2017).
MedlineGoogle Scholar
36. Haroche J, Cohen-Aubart F, Emile JF et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J. Clin. Oncol. 33(5), 411–418 (2015).
Medline CASGoogle Scholar
37. Euskirchen P, Haroche J, Emile JF, Buchert R, Vandersee S, Meisel A. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflamm 2(2), e78 (2015).
MedlineGoogle Scholar
38. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342(1), 33–40 (2012).
Medline CASGoogle Scholar
39. Davies MA, Saiag P, Robert C et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7), 863–873 (2017).
Medline CASGoogle Scholar
40. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 344(3), 655–664 (2013).
Medline CASGoogle Scholar
41. Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. JAMA Oncol 1(8), 1133–1134 (2015).
MedlineGoogle Scholar
42. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2), 122–136 (2015).
Medline CASGoogle Scholar
43. Bhatia A, Ulaner G, Rampal R et al. Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis. Haematologica 103(4), e177–e180 (2018).
Medline CASGoogle Scholar
44. Costa S, Juliao MJ, Silva S, Brito MJ. Erdheim-Chester disease: a rare non-Langerhans histiocytosis. BMJ Case Rep 14(9), (2021).
Google Scholar
45. Hao X, Feng R, Bi Y et al. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. J Neurosurg Pediatr 23(1), 48–53 (2018).
MedlineGoogle Scholar
46. Cohen Aubart F, Emile JF, Carrat F et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 130(11), 1377–1380 (2017).
MedlineGoogle Scholar
47. Brodie J, Zhou S, Makkuni D et al. Erdheim-Chester Disease: two cases from an ophthalmic perspective. Am J Ophthalmol Case Rep 20, 100984 (2020).
MedlineGoogle Scholar
48. Park JK, Huang LC, Kossler AL. Erdheim-Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes. Orbit 42(3), 233–244 (2023).
MedlineGoogle Scholar
49. Huang LC, Topping KL, Gratzinger D et al. Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib. Am J Ophthalmol Case Rep 11, 158–163 (2018).
MedlineGoogle Scholar
50. Grumbine FL, Aderman C, Vagefi MR, Kersten RC. Orbital MRI Pre- and Post-Vemurafenib Therapy for Erdheim-Chester Disease. Ophthalmic Plast Reconstr Surg 31(6), e169 (2015).
MedlineGoogle Scholar
51. Gupta A, Yeganeh A, Rootman D, Goldberg R. Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease. Ophthalmic Plast Reconstr Surg 33(6), e138–e139 (2017).
MedlineGoogle Scholar
52. Nordmann TM, Juengling FD, Recher M et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Blood 129(7), 879–882 (2017).
Medline CASGoogle Scholar
53. King AJ, Arnone MR, Bleam MR et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLOS ONE 8(7), e67583 (2013).
Medline CASGoogle Scholar
54. Grob JJ, Amonkar MM, Karaszewska B et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 16(13), 1389–1398 (2015).
Medline CASGoogle Scholar
55. Mazor RD, Weissman R, Luckman J et al. Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. Neurooncol Adv 2(1), vdaa024 (2020).
MedlineGoogle Scholar

Ahead of Print

Metrics

Downloaded 41 times

History

Received 23 November 2023

Accepted 15 January 2024

Published online 26 January 2024

Information

Keywords

Author contributions

C Yuen - study concept, data collection, analysis, interpretation, manuscript drafting, revision and final approval. S Bao - study concept, data collection, analysis, interpretation and final approval. M Sandi Aung & R Shishodia - data collection and final approval. X-T Kong - manuscript revision and final approval.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

X-T Kong received honorarium from Zai Lab for invited speeches for symposiums prior to July 2021. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved. Ethics approval and consent to participate: need for ethics approval was needed. Consent for publication: written consent was obtained. Availability of data and material: the datasets from this study are available from the corresponding author upon reasonable request. Funding: no funding was received for this manuscript.

PDF download